Literature DB >> 14574326

Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway.

K U Birkenkamp1, M Geugien, H Schepers, J Westra, H H Lemmink, E Vellenga.   

Abstract

In the present study, we aimed to elucidate the mechanism responsible for constitutive NF-kappaB DNA-binding activity in AML cells. Intervening in aberrant signaling pathway provides a rational approach for in vivo targeting of AML cells. Constitutive NF-kappaB DNA-binding activity was observed in 16 of 22 (73%) investigated AML cases and was, in general, associated with resistance to spontaneous apoptosis. Indeed, inhibition of NF-kappaB activity by the NF-kappaB inhibitor SN-50 peptide resulted in enhanced chemotherapy-induced apoptosis. In the majority of cases, constitutive NF-kappaB activity was mediated by a Ras/PI3 kinase (PI3-K)/protein kinase B (PKB)-mediated pathway. The PI3-K inhibitor Ly294002 and the Ras inhibitor L-744832 both inhibited PKB phosphorylation and NF-kappaB DNA-binding activity. The constitutive activation of Ras GTP-ase was caused by mutations in the gene encoding for N-Ras in 29% of the cases. The constitutive NF-kappaB activity could so far not be ascribed to the autocrine production of growth factors or to mutations in the Flt3 receptor, since anti-GM-CSF, -IL-1, -IL6, -TNFalpha or the tyrosine kinase inhibitor AG1296 did not affect the NF-kappaB DNA-binding activity. The present study demonstrates that Ras activation is an important pathway for triggering the NF-kappaB pathway in AML cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14574326     DOI: 10.1038/sj.leu.2403145

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

Review 1.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

2.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

3.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Authors:  Carmen P Montano-Almendras; Ahmed Essaghir; Hélène Schoemans; Inci Varis; Laura A Noël; Amélie I Velghe; Dominique Latinne; Laurent Knoops; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

4.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

5.  The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.

Authors:  Mohamed Rahmani; Anh Anderson; Joseph Reza Habibi; Timothy Ryan Crabtree; Mandy Mayo; Hisashi Harada; Andrea Ferreira-Gonzalez; Paul Dent; Steven Grant
Journal:  Blood       Date:  2009-09-22       Impact factor: 22.113

Review 6.  DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out.

Authors:  Kevin W McCool; Shigeki Miyamoto
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

7.  Epigenetic roles of MLL oncoproteins are dependent on NF-κB.

Authors:  Hsu-Ping Kuo; Zhong Wang; Dung-Fang Lee; Masayuki Iwasaki; Jesus Duque-Afonso; Stephen H K Wong; Chiou-Hong Lin; Maria E Figueroa; Jie Su; Ihor R Lemischka; Michael L Cleary
Journal:  Cancer Cell       Date:  2013-09-19       Impact factor: 31.743

8.  Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.

Authors:  Qinghang Meng; Zhimin Peng; Liang Chen; Jutong Si; Zhongyun Dong; Ying Xia
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

9.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.

Authors:  Zhongzheng Lu; Yanli Jin; Chun Chen; Juan Li; Qi Cao; Jingxuan Pan
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.